New York State Common Retirement Fund Sells 30,071 Shares of Haemonetics Co. (NYSE:HAE)

New York State Common Retirement Fund cut its position in shares of Haemonetics Co. (NYSE:HAE) by 49.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,702 shares of the medical instruments supplier’s stock after selling 30,071 shares during the quarter. New York State Common Retirement Fund owned approximately 0.06% of Haemonetics worth $2,625,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Haemonetics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock valued at $482,017,000 after purchasing an additional 27,146 shares during the last quarter. Kingdon Capital Management L.L.C. bought a new position in shares of Haemonetics during the 3rd quarter valued at about $9,952,000. Lazard Asset Management LLC increased its position in shares of Haemonetics by 114.2% during the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock valued at $3,452,000 after purchasing an additional 20,550 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of Haemonetics by 1.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock valued at $4,753,000 after purchasing an additional 586 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its position in shares of Haemonetics by 2.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock valued at $24,065,000 after purchasing an additional 6,828 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Trading Up 1.0 %

Shares of HAE stock opened at $95.35 on Tuesday. The stock has a market capitalization of $4.84 billion, a PE ratio of 38.76, a P/E/G ratio of 2.23 and a beta of 0.34. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $96.25. The business has a 50-day moving average of $82.81 and a 200 day moving average of $82.69. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter last year, the business posted $0.85 EPS. The business’s revenue was up 10.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Haemonetics Co. will post 3.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HAE has been the subject of several analyst reports. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.